Protecting Cancer Patients Against COVID-19: New Strains, New Vaccines, One Year from Vaccine Approvals
Chair’s welcome
It is with great pleasure that I invite you to participate in the second webinar of a new ESMO short series: Protecting Cancer Patients against COVID-19, which will focus on new variants, vaccines and therapeutics and summarise evidence available one-year post-COVID-19 vaccines approvals.
This webinar is developed with the aim to provide an overview of efficacy of COVID-19 vaccines in patients with cancer while new variants are emerging. It will also highlight novel technologies and provide insights in research progress on second generation vaccine development.
I am delighted to announce the distinguished speakers who will join me in this webinar. We will begin with a lecture on emergence of new variants of concern by covering mechanisms, impact on herd immunity and mitigation strategies. This will follow with elaboration on ongoing research in second generation of COVID-19 vaccines and novel technologies. Finally, we will evaluate the efficacy and safety of COVID-19 vaccines and therapeutics in people with cancer in the context of clinical trials, registries, or retrospective real-world data.
The programme is designed to provide an overview of the current evidence, offer expert opinion exchange, and provide some important considerations with regard to new virus variants and new vaccines one year from first vaccine approvals. I strongly encourage and invite you to register and join us all in this new ESMO activity.
Prof. John Haanen
Netherlands Cancer Institute, Amsterdam, Netherlands
Speakers
Programme
Time |
Title |
Speaker |
|---|---|---|
5 min |
Welcome and Introduction |
John B. Haanen |
20 min |
Ongoing research in 2nd generation anti-SARS-CoV-2 vaccines and novel technologies |
Danny Altmann |
15 min |
Evaluating the efficacy and safety of anti-SARS-CoV-2 vaccines and therapeutics in people with cancer: trials, registries or retrospective RWD? |
Petros Grivas |
15 min |
LIVE Q&A |
All |
*Programme changed due to unforeseen circumstances
A certificate of attendance and 1 ESMO MORA category point will be awarded for live attendance to this event.
Learning objectives:
- To provide an updated overview of efficacy and safety of anti-SARS-CoV-2 vaccines in patients with cancer
- To highlight emerging data on monitoring and enhancing vaccine-induced immunity
- To highlight therapeutic interventions beyond vaccines for the prevention of severe morbidity and mortality in immunosuppressed or high-risk patients
- To provide insights in research progress on second generation vaccine development
Supported by
